Skip to main content

Safirstein Metcalf LLP and HGT Law Commence a Securities Fraud Action Against Valeant Pharmaceuticals (VRX) and its Senior Officers on Behalf of Retail Investors

On January 19, 2018, Safirstein Metcalf LLP and HGT Law commenced a shareholder “opt-out” lawsuit  on behalf of a group of retail investors against Valeant Pharmaceuticals International, Inc. (NYSE:VRX) and its senior officers for violations of federal securities laws.

The class action is brought on behalf of purchasers of Valeant equity securities and senior notes between January 4, 2013 and March 15, 2016.

A copy of the complaint filed by Safirstein Metcalf LLP and HGT Law on behalf of the Investors is located at

If you purchased Valeant common stock during the Class Period and suffered losses of more than $200,000, then you may wish to consider opting out of the existing class action.  If you would like to learn about the options available to you, please use the form located on this page, call 1-800-221-0015, email or visit

Previously, on June 24, 2016, a class action complaint was filed in the U.S. District Court for the District of New Jersey, on behalf of a class consisting of all purchasers of the common stock of Valeant.  The Investors have opted out of the Class Action to directly pursue their own claims.  To date, this Lawsuit is the only opt-out action that has been filed on behalf of retail investors.

Attorney advertising.  Prior results do not guarantee a similar outcome.